Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alcon Inc.
Industry Sector: HealthTechnology
CEO: David J. Endicott, MBA
Number Of Employees: 25,599
Enterprise Value: $45,700,973,505
PE Ratio: 43.19
Exchange/Ticker 1: SIX:ALC
Exchange/Ticker 2: NYSE:ALC
Latest Market Cap: $43,772,982,035
BioCentury | Feb 1, 2025
Finance
Metsera, Maze land on NASDAQ as IPO queue grows
BioCentury’s Public Equity Report: MASH data drive follow-ons for Akero, 89bio
BioCentury | Aug 14, 2024
Deals
Deals Report: Pair of Merck deals in APAC region; Recursion and Exscientia merging
Plus: Denmark-based Pharmacosmos buys G1, obtaining myelosuppression drug
BioCentury | Oct 12, 2023
Product Development
Slimmed down Novartis is now poised to grow value, says CEO Narasimhan
How Vas Narasimhan is managing change as he continues to chart a new course for the pharma
BioCentury | Nov 2, 2022
Management Tracks
New heads of commercial, legal at ADC
Plus Antares vet Powell lands at Lava, and updates from CymaBay, Lineage, CARsgen and more
BioCentury | Aug 25, 2022
Deals
Sandoz spinout last step in Novartis’ transformation into pure-play innovative medicines company
Move comes amid reorganization prioritizing multibillion growth drivers, the U.S. market
BioCentury | Aug 23, 2022
Deals
Biotech’s trend of commercial stage M&A continues with Alcon takeout of Aerie
Deal values Aerie at $770M with a 37% premium
BioCentury | May 23, 2022
Deals
Kala, Catalyst Biosciences sell off programs, each padding cash reserves with $60M
Sign of the times: strategic decisions extend Kala’s runway, prepare Catalyst for next step
BioCentury | Apr 13, 2022
Emerging Company Profile
Aurion attracts new investors for corneal cell therapy
Seattle company, with roots in Japan, raises $120M to fund U.S., EU development of therapy to restore vision in patients with corneal endothelial disorders
BioCentury | Apr 4, 2022
Product Development
Novartis’ new page prioritizes ‘high-value’ multibillion dollar assets
Narasimhan’s restructuring reunites oncology with rest of pharma, creates new role of chief strategy & growth officer
BioCentury | Aug 27, 2021
Management Tracks
Pfizer names McKinsey vet Malik to succeed Young
Plus: Lonza, Renovacor, Lilly, Adamis, NeoImmuneTech and more
Items per page:
1 - 10 of 212